Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

118 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-01

Study Completion Date

2027-04-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis. Likewise, genetic testing of ovarian cancer patients for these germline mutations provides invaluable information for families regarding cancer risk, genetic testing, and subsequently indication for risk-reducing surgery. Cascade testing provides a unique opportunity to identify carriers of a deleterious BRCA mutation which can allow for surgical and chemoprevention of prevention of ovarian cancer. There is currently no literature on the rates of referral for the family members.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

NCT00858078

BRCA1 Gene BRCA2 Gene

COMPLETED

Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland

NCT03124212

Hereditary Breast and Ovarian Cancer Lynch Syndrome

RECRUITING

Clinical Significance of Germline BRCA Mutations

NCT00579488

Breast Cancer Ovarian Cancer

ACTIVE_NOT_RECRUITING

Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes

NCT06914726

Hereditary Breast/Ovarian Cancer (brca1, brca2) Lynch Syndrome Genetic Variation +2 more

ENROLLING_BY_INVITATION NA

Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer

NCT02560818

Breast Cancer Transcriptomes Molecular Diagnostic +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to perform a pilot study, offering referral to a genetic counseling and genetic testing for family members of a probands known to have a mutation in BRCA1 or BRCA2. In addition to BRCA1 and BRCA2, the NCCN suggests consideration of risk-reducing surgery for mutations in BRIP1, MSH2, MLH1, MSH6, PMS2, EPCAM, RAD51C, RAD51D, investigators will include these subjects as well in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

BRCA-Mutated Ovarian Carcinoma BRIP1 Gene Mutation MSH2 A636P MLH1 Gene Mutation MSH6 Gene Mutation PMS2 Gene Mutation EPCAM RAD51C Gene Mutation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Successful Cascade Testing

Genetic counselor contacts relatives and offers participation in study. Relative accepts and genetic testing in performed.

CASCADE genetic screening

Intervention Type OTHER

Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives

Relative Declines Genetic Testing

Genetic counselor contacts relatives and offers participation in study. Relative declines and genetic testing is not performed.

CASCADE genetic screening

Intervention Type OTHER

Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CASCADE genetic screening

Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All subjects must have a diagnosis of epithelial ovarian cancer, Fallopian tube caner or primary peritoneal cancer with a known pathogenic genetic mutation.
* All subjects must agree to participate.
* All subjects must have first or second degree relatives who have not been diagnosed with the same genetic mutation.
* A previous diagnosis of cancer in the subject's first or second degree relative is allowed.

Exclusion Criteria

* Subjects whose first and/or second degree relatives have already been tested with the subject's known mutations, and no other viable family members are available for testing.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes